Accessibility StatementSkip Navigation About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertis ...

Core Insights - WuXi Biologics has been recognized on the CDP's A List for Supplier Engagement Assessment, highlighting its leadership in climate-related supply chain engagement [1][2] - The company has achieved a 30% reduction in GHG emissions intensity (Scope 1 and Scope 2) in 2024 compared to the base year 2020, with a goal of net-zero emissions by 2050 [3][4] - WuXi Biologics has received multiple recognitions for its sustainability efforts, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices [4][9] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [6][8] - The company employs over 12,000 skilled professionals across various countries, supporting 817 integrated client projects as of December 31, 2024 [8] - Sustainability is a cornerstone of WuXi Biologics' long-term business strategy, focusing on green technology innovations and responsible practices [9] Environmental Commitment - WuXi Biologics is committed to the Science Based Target initiative (SBTi) and has established measurable targets for climate change [3] - The company actively engages with suppliers to enhance sustainable supply chain management and Scope 3 emissions reporting [3][4] - WuXi Biologics has been recognized for its water security efforts, being included in CDP's Water Security A List [2][4] Recognition and Ratings - The company has received leadership-level scores from CDP for two consecutive years, reflecting its commitment to climate change initiatives [2][4] - WuXi Biologics has been awarded an EcoVadis Platinum Medal and recognized as a top-rated company by Sustainalytics for five consecutive years [4][9] - The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, further emphasizing its dedication to sustainability [4]